Pensionfund Sabic Cuts Stake in Agilent Technologies, Inc. $A

Pensionfund Sabic lessened its holdings in shares of Agilent Technologies, Inc. (NYSE:A) by 8.6% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 9,600 shares of the medical research company’s stock after selling 900 shares during the period. Pensionfund Sabic’s holdings in Agilent Technologies were worth $1,123,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of A. Generation Investment Management LLP grew its stake in Agilent Technologies by 19.8% during the 1st quarter. Generation Investment Management LLP now owns 4,983,556 shares of the medical research company’s stock valued at $582,976,000 after acquiring an additional 824,243 shares in the last quarter. GAMMA Investing LLC grew its stake in Agilent Technologies by 15,648.1% during the 1st quarter. GAMMA Investing LLC now owns 627,247 shares of the medical research company’s stock valued at $73,375,000 after acquiring an additional 623,264 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in Agilent Technologies by 18.7% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 3,836,105 shares of the medical research company’s stock valued at $448,748,000 after acquiring an additional 604,124 shares in the last quarter. Two Sigma Investments LP grew its stake in Agilent Technologies by 345.9% during the 4th quarter. Two Sigma Investments LP now owns 769,897 shares of the medical research company’s stock valued at $103,428,000 after acquiring an additional 597,249 shares in the last quarter. Finally, Mackenzie Financial Corp grew its stake in Agilent Technologies by 141.5% during the 1st quarter. Mackenzie Financial Corp now owns 935,893 shares of the medical research company’s stock valued at $109,481,000 after acquiring an additional 548,344 shares in the last quarter. Hedge funds and other institutional investors own 87.41% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently issued reports on A shares. Robert W. Baird upped their price objective on shares of Agilent Technologies from $141.00 to $142.00 and gave the company an “outperform” rating in a research note on Thursday, August 28th. Wells Fargo & Company increased their price target on shares of Agilent Technologies from $135.00 to $140.00 and gave the company an “overweight” rating in a research note on Thursday, August 28th. Evercore ISI dropped their price target on shares of Agilent Technologies from $130.00 to $128.00 and set an “in-line” rating for the company in a research note on Thursday, August 28th. JPMorgan Chase & Co. dropped their price target on shares of Agilent Technologies from $160.00 to $155.00 and set an “overweight” rating for the company in a research note on Thursday, May 29th. Finally, Wall Street Zen cut shares of Agilent Technologies from a “buy” rating to a “hold” rating in a research note on Friday, September 5th. Six investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $139.25.

Insider Transactions at Agilent Technologies

In other Agilent Technologies news, CEO Padraig Mcdonnell sold 1,508 shares of the stock in a transaction that occurred on Tuesday, July 1st. The shares were sold at an average price of $117.44, for a total transaction of $177,099.52. Following the sale, the chief executive officer directly owned 37,448 shares in the company, valued at $4,397,893.12. This represents a 3.87% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.26% of the stock is currently owned by company insiders.

Agilent Technologies Stock Performance

Shares of A stock opened at $123.19 on Friday. The firm’s 50 day moving average price is $119.76 and its 200-day moving average price is $115.87. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.71 and a current ratio of 2.25. Agilent Technologies, Inc. has a one year low of $96.43 and a one year high of $153.84. The firm has a market cap of $34.92 billion, a P/E ratio of 28.92, a P/E/G ratio of 3.94 and a beta of 1.24.

Agilent Technologies (NYSE:A) last issued its quarterly earnings data on Wednesday, August 27th. The medical research company reported $1.37 EPS for the quarter, hitting the consensus estimate of $1.37. Agilent Technologies had a net margin of 17.97% and a return on equity of 25.51%. The firm had revenue of $1.74 billion for the quarter, compared to analyst estimates of $1.67 billion. During the same period in the prior year, the business posted $1.32 EPS. The business’s revenue for the quarter was up 10.1% compared to the same quarter last year. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS. As a group, equities research analysts predict that Agilent Technologies, Inc. will post 5.58 EPS for the current year.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.